Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2A in Pediatric Immune-Tolerant Chronic Hepatitis B
NCT02263079Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Jan 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at Week 80. Started Jun 2014; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02263079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263079.